Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 22 Results

Title
Intervention Indication Therapeutic Area Year Actions
177Lu-PSMA-617 for metastatic castrationresistant prostate cancer - third line Lutetium (177Lu-PSMA-617; 177Lu-DOTA-tyr3-octreotate; Lutathera) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Apalutamide in Addition to Abiraterone and Prednisone/Prednisolone for Metastatic Castration-resistant Prostate Cancer – First Line Abiraterone acetate (Zytiga; Yonsa) , Apalutamide (Erleada; ARN-509) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Apalutamide in addition to androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Apalutamide (Erleada; ARN-509) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Darolutamide for Non‐metastatic, Castration-resistant Prostate Cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Darolutamide in addition to docetaxel and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer Darolutamide (ODM-201; BAY-1841788; Nubeqa) , Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) Prostate cancer Male Reproductive Cancer 2021 View  |  Download
Enzalutamide (Xtandi) for non-metastatic prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2017 View  |  Download
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy Enzalutamide (Xtandi; MDV3100) Non-metastatic prostate cancer Male Reproductive Cancer 2022 View  |  Download
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer Enzalutamide (Xtandi; MDV3100) Prostate cancer Male Reproductive Cancer 2019 View  |  Download
Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line Abiraterone acetate (Zytiga; Yonsa) , Ipatasertib (GDC-0068; RG7440) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Niraparib for metastatic castration-resistant prostate cancer with DNA-repair anomalies Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications